This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PharMerica Reports Results For The Second Quarter Of 2013

Stocks in this article: PMC

PharMerica Corporation (NYSE: PMC), a national provider of pharmacy services, today reported its financial results for the second quarter and six months ended June 30, 2013.

Commenting on the Company’s results, Greg Weishar, PharMerica Corporation’s Chief Executive Officer, said, “This quarter’s results continue the strong operating performance we realized last quarter. On a sequential quarter basis, the Company maintained its record setting first quarter 2013 quarterly gross margin percent of 19.2%. Adjusted EBITDA margin was equally strong at 7.8%; just shy of the 7.9% record we established last quarter. Moreover, on a year over year basis, Adjusted EBITDA increased 26% to $33.7 million and Adjusted EBITDA margin increased 200 basis points to 7.8%.

“Last quarter we indicated we were seeing improvement in sales and client retention. We see this trend continuing and expect further momentum as we head into the last half of the year. Excluding Golden Living and Kindred, bed losses have fallen significantly and the sales pipeline is growing and beginning to generate new sales. We believe our superior cost containment programs and pharmacy services are leading to improvement in client retention and firmly believe the Company is well positioned to aggressively compete in the long term care market segment.

“Amerita, the specialty home infusion company that we acquired in December 2012, saw impressive operating earnings growth on a sequential basis. Operating earnings improved 50% in the second quarter of 2013 versus the strong first quarter of 2013. Recall, Amerita was accretive to earnings last quarter and we expect continued growth as Amerita’s prospects remain bright.

“Cash flow for the quarter was $26.6 million bringing our year to date cash flow to $74.3 million, an increase of 43% over the first half of 2012.

“Finally, based on the strong performance for the first six months of 2013, PharMerica now expects the following for the full year 2013:

 
    Previous Guidance   Current Guidance
Revenues   $1.567B to $1.694B   $1.625B to $1.675B
Adjusted diluted earnings per share $1.39 to $1.55 $1.55 to $1.60
Cash flows from operations*       $85M to $95M
 

*Cash flows from operations was not provided in previous guidance.

 

Note: The full year guidance excludes the impact of any acquisitions or restructuring charges that may be incurred by the Company.

 

The results for the second quarter are set forth below:

  • Key Comparisons of Second Quarters Ended June 30, 2013 and 2012:
    • Net income for the second quarter of 2013 was $10.2 million, or $0.34 diluted earnings per share, compared with $7.6 million, or $0.26 diluted earnings per share, for the same period in 2012. Adjusted diluted earnings per share were $0.44 in 2013 compared with $0.35 adjusted diluted earnings per share in 2012, an increase of 25.7%.
    • Adjusted EBITDA for the second quarter of 2013 was $33.7 million compared with $26.7 million in the second quarter of 2012, an increase of 26.2%.
    • Gross profit for the second quarter of 2013 was $82.6 million compared with $75.9 million in the second quarter of 2012. Gross margin expanded 260 basis points to 19.2% in the second quarter of 2013 compared with 16.6% in the second quarter of 2012.
    • Revenues for the second quarter of 2013 were $430.8 million compared with $458.5 million for the second quarter of 2012, a decrease of 6.0%.
    • Cash flows provided by operating activities for the second quarter of 2013 were $26.6 million compared with cash flows provided by operating activities of $31.9 million in the second quarter of 2012, a decrease of 16.6%.
  • Key Comparisons of Six Months Ended June 30, 2013 and 2012:
    • Net income for the six months ended June 30, 2013, was $20.7 million, or $0.69 diluted earnings per share, compared with $13.2 million, or $0.44 diluted earnings per share, for the same period in 2012. Adjusted diluted earnings per share were $0.90 in the first half of 2013 compared with $0.67 adjusted diluted earnings per share in the same period in 2012, an increase of 34.3%.
    • Adjusted EBITDA for the first half of 2013 was $68.3 million compared with $53.5 million in the first half of 2012, an increase of 27.7%.
    • Gross profit for the six months ended June 30, 2013, was $166.9 million, or 19.2% of revenue, compared with $148.5 million, or 15.5% of revenue, in the same period of 2012. Gross margin expanded 370 basis points to 19.2% in the first half of 2013 compared with 15.5% in the first half of 2012.
    • Revenues for the six months ended June 30, 2013, were $870.6 million compared with $957.4 million for the same period of 2012, a decrease of 9.1%.
    • Cash flows provided by operating activities were $74.3 million compared with $51.8 million in the same period of 2012, an increase of 43.4%.

Conference Call

Management will hold a conference call to review the financial results for the second quarter on August 2, 2013, at 10:00 a.m. Eastern Time. To access the live webcast, visit the Investor Relations section of the Company’s website at www.pharmerica.com. To access a telephonic replay of the call, which will be available one hour after the conclusion of the call through August 16, 2013, please dial 1-888-286-8010 (617-801-6888 if calling from outside the U.S.) and use passcode 78855441.

About PharMerica

PharMerica Corporation is a leading institutional pharmacy services company that services healthcare facilities in the United States, provides pharmacy management services to hospitals, and also provides specialty infusion services to patients outside a hospital setting. As of June 30, 2013, PharMerica operated 90 institutional pharmacies and 12 specialty infusion centers in 45 states. PharMerica’s customers are institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care providers.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs